Literature DB >> 17935696

X-ray crystal structure of TNF ligand family member TL1A at 2.1A.

Tengchuan Jin1, Feng Guo, Sunghee Kim, Andrew Howard, Yu-Zhu Zhang.   

Abstract

The TNF family has been one of the most intensively studied protein families in the past two decades and it has rapidly expanded through the era of genomics and bioinformatics. However, the structural basis of the functional and interactional similarities and differences of this family is poorly understood. TL1A is a recently identified TNF family member that has received increasing attention. Here, the crystal structure of human TL1A is reported. TL1A forms a homotrimer with each monomer assuming a jellyroll beta-sandwich fold. The CD loop in TL1A is the longest among the TNF ligand members with known structure and the AA' loop in TL1A is the second longest after that in TRAIL, where part of it is disordered. Both these loops are known to participate in receptor binding in TNFbeta/LTalpha. The AA' loop may be very different in other TL1A variants if the overall fold is to be preserved.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17935696     DOI: 10.1016/j.bbrc.2007.09.097

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  15 in total

Review 1.  TL1A and DR3, a TNF family ligand-receptor pair that promotes lymphocyte costimulation, mucosal hyperplasia, and autoimmune inflammation.

Authors:  Françoise Meylan; Arianne C Richard; Richard M Siegel
Journal:  Immunol Rev       Date:  2011-11       Impact factor: 12.988

2.  Hydrogen/deuterium exchange mass spectrometry and computational modeling reveal a discontinuous epitope of an antibody/TL1A Interaction.

Authors:  Richard Y-C Huang; Stanley R Krystek; Nathan Felix; Robert F Graziano; Mohan Srinivasan; Achal Pashine; Guodong Chen
Journal:  MAbs       Date:  2017-11-14       Impact factor: 5.857

3.  Decoy strategies: the structure of TL1A:DcR3 complex.

Authors:  Chenyang Zhan; Yury Patskovsky; Qingrong Yan; Zhenhong Li; Udupi Ramagopal; Huiyong Cheng; Michael Brenowitz; Xiao Hui; Stanley G Nathenson; Steven C Almo
Journal:  Structure       Date:  2011-02-09       Impact factor: 5.006

4.  Approaches to efficient production of recombinant angiogenesis inhibitor rhVEGI-192 and characterization of its structure and antiangiogenic function.

Authors:  Xu Chen; Jueheng Wu; Hanning Liu; Zhenjian He; Minghui Gu; Ning Wang; Jianda Ma; Jieping Hu; Lei Xia; Haipeng He; Jie Yuan; Jun Li; Luyuan Li; Mengfeng Li; Xun Zhu
Journal:  Protein Sci       Date:  2010-03       Impact factor: 6.725

5.  TNFSF15 Modulates Neovascularization and Inflammation.

Authors:  Zhisong Zhang; Lu-Yuan Li
Journal:  Cancer Microenviron       Date:  2012-07-26

Review 6.  Immunobiology of TNFSF15 and TNFRSF25.

Authors:  Taylor H Schreiber; Eckhard R Podack
Journal:  Immunol Res       Date:  2013-12       Impact factor: 2.829

7.  Biochemical and structural characterization of the human TL1A ectodomain.

Authors:  Chenyang Zhan; Qingrong Yan; Yury Patskovsky; Zhenhong Li; Rafael Toro; Amanda Meyer; Huiyong Cheng; Michael Brenowitz; Stanley G Nathenson; Steven C Almo
Journal:  Biochemistry       Date:  2009-08-18       Impact factor: 3.162

8.  Two functionally distinct isoforms of TL1A (TNFSF15) generated by differential ectodomain shedding.

Authors:  Christoph Mück; Dietmar Herndler-Brandstetter; Lucia Micutkova; Beatrix Grubeck-Loebenstein; Pidder Jansen-Dürr
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2010-07-30       Impact factor: 6.053

Review 9.  Principles of antibody-mediated TNF receptor activation.

Authors:  H Wajant
Journal:  Cell Death Differ       Date:  2015-08-21       Impact factor: 15.828

10.  The TNF-family cytokine TL1A inhibits proliferation of human activated B cells.

Authors:  Chiara Cavallini; Ornella Lovato; Anna Bertolaso; Luciano Pacelli; Elisa Zoratti; Elisabetta Zanolin; Mauro Krampera; Alberto Zamò; Cristina Tecchio; Marco A Cassatella; Giovanni Pizzolo; Maria T Scupoli
Journal:  PLoS One       Date:  2013-04-02       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.